The partners said March 3 that the partnership’s main goal is the development of the soft tissue surgery medical devices industry, which lags behind its orthopedic and cardiologic equivalents.
“Having [the Hospital for Endocrine Surgery’s team] in our facility on a regular basis to meet with and collaborate with biologic companies and device manufacturers is expected to speed up their new product development, ultimately resulting in better cure rates and better outcomes,” Five Labs CEO Derek Pupello said in a statement.
The surgeons and Five Labs will also host annual device, biologics and training conferences for all soft tissue surgeons including endocrine surgeons, surgical oncologists and ENT surgeons.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
